6 recruiting, 2 completed, 1 active not recruiting, 1 withdrawn. 8 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 4, Completed 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 7 | Recruiting 5, Active not recruiting 1, Withdrawn 1 |
Follow IN10018: new trials by email Literature Review of IN10018 trials Research Report on IN10018
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IN10018 Combination Therapy in Previously-treated Solid Tumors IN10018, Nab-paclitaxel, Tislelizumab - Solid Tumor | Phase 1 / Phase 2 | Withdrawn | InxMed (Shanghai) Co., Ltd. | 2025-08-13 | 2026-03-27 | |
| A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation JMKX001899, IN10018, Chemotherapy: Pemetrexed - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | Recruiting | Jemincare | 72 | 2025-06-06 | 2025-07-01 |
| IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial IN10018, Nab-paclitaxel, Cadonilimab - Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 25 | 2025-02-17 | 2026-01-13 |
| IN10018 Combination Therapy in Treatment-naïve ES-SCLC IN10018, Tislelizumab, Carboplatin - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 120 | 2023-10-30 | 2025-04-30 |
| IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC IN10018, Furmonertinib - NSCLC | Phase 1 / Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 110 | 2023-07-13 | 2025-04-30 |
| IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer IN10018, Albumin-Bound Paclitaxel, Gemcitabine - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 70 | 2022-12-08 | 2025-04-30 |
| Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors D-1553, IN10018 - Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | InventisBio Co., Ltd | 92 | 2022-10-12 | 2026-07-17 |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin - Ovarian Cancer Recurrent | Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 168 | 2022-09-06 | 2025-04-30 |
| IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma IN10018, Docetaxel - Gastric Cancer | Phase 1 | Completed | InxMed (Shanghai) Co., Ltd. | 33 | 2020-07-09 | 2022-11-16 |
| IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma IN10018, Cobimetinib, Atezolizumab - Metastatic Melanoma | Phase 1 | Completed | InxMed (Shanghai) Co., Ltd. | 51 | 2020-03-16 | 2026-01-15 |
Carcinoma, Non-Small-Cell Lung (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
InxMed (Shanghai) Co., Ltd. (7) · InventisBio Co., Ltd (1) · Jemincare (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (8) · Australia (1) · United States (1)
Caicun Zhou (1) · Eddie Xing, Dr. (1) · Jifeng Feng (1) · Jin Li, Doctor (1) · Jun Zhao (1) · Lingying WU (1) · Liwei Wang (1) · Peng Wu, Ph.D (1) · Yilong Wu (1) · Zhengbo Song (1)